drugset
drugset / Trial / NCT00842127

Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)

NCT00842127 ↗

Phase 4 Completed 150 enrolled Bundang CHA Hospital Hallym University Medical Center · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine whether genetic polymorphisms in drug transporters were associated with the side effects of OROS-methylphenidate medication in attention deficit/hyperactivity disorder(ADHD).

Timeline

Start
2006-03
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 18 mg —
Subject Methylphenidate Small molecule 27 mg —
Subject Methylphenidate Small molecule 36 mg —
Subject Methylphenidate Small molecule 45 mg —
Subject Methylphenidate Small molecule 54 mg —

Indications

attention deficit-hyperactivity disorder